FLOVENT HFA Rx
Generic Name and Formulations:
Fluticasone propionate 44mcg/inh, 110mcg/inh, 220mcg/inh; metered dose inhaler; CFC-free.
Indications for FLOVENT HFA:
Maintenance treatment of asthma as prophylactic therapy.
Limitations Of use:
Not for the relief of acute bronchospasm.
Previously on bronchodilators alone: initially 88mcg twice daily (approx. 12hrs apart); max 880mcg twice daily. Rinse mouth after use. Titrate to lowest effective dose after stability achieved. Re-evaluate if inadequate control.
<4yrs: not established. 4–11yrs: 88mcg twice daily (approx. 12hrs apart). Rinse mouth after use. Titrate to lowest effective dose after stability achieved. Re-evaluate if inadequate control.
Primary treatment of status asthmaticus or other acute attacks requiring intensive measures.
Maintain regular regimen. Infections. If exposed to chickenpox or measles, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Change in vision or history of increased intraocular pressure, glaucoma, and/or cataracts; monitor. Monitor for reduction in bone mineral density if other osteoporosis risk factors exist; and for growth suppression in children; hypercorticism and HPA axis suppression (if occur discontinue gradually). Eosinophilic conditions. Hepatic impairment (monitor). Transferring from oral corticosteroids: see full labeling. Pregnancy. Nursing mothers.
Concomitant strong CYP3A4 inhibitors (eg, ritonavir, ketoconazole): not recommended.
Upper respiratory infection/inflammation, throat irritation, sinusitis, dysphonia, candidiasis, cough, bronchitis, headache; immunosuppression, adrenal suppression, bronchospasm.
Inhaler w. actuator (44mcg)—10.6g (120 inh); 110mcg, 220mcg—12g (120 inh)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders